GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (LTS:0A4W) » Definitions » Repurchase of Stock

ACADIA Pharmaceuticals (LTS:0A4W) Repurchase of Stock : $0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is ACADIA Pharmaceuticals Repurchase of Stock?

ACADIA Pharmaceuticals's Repurchase of Stock for the three months ended in Dec. 2024 was $0.0 Mil.

ACADIA Pharmaceuticals's Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was $0.0 Mil.


ACADIA Pharmaceuticals Repurchase of Stock Historical Data

The historical data trend for ACADIA Pharmaceuticals's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Repurchase of Stock Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ACADIA Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ACADIA Pharmaceuticals Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ACADIA Pharmaceuticals Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Headlines

No Headlines